The Higgins Firm Investigating Dupixent Claims After FDA Flags Skin Cancer Risk

The Higgins Firm, a Nashville-based personal injury law firm, is actively investigating claims involving Dupixent (dupilumab), a widely prescribed biologic medication that has been linked to an increased risk of cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer.

Multiple peer-reviewed studies have found that patients treated with Dupixent are over four times more likely to develop CTCL compared to patients who did not use the drug. In March 2025, the FDA added Dupixent to its Potential Signals of Serious Risks list after receiving more than 300 reports of CTCL linked to the medication. As of 2026, Dupixent’s warning label still contains no mention of cancer risk.

“Patients trusted this drug to treat their eczema,” said Jim Higgins, founder of The Higgins Firm. “What they weren’t told is that CTCL — the cancer now linked to Dupixent — looks almost identical to eczema. That means some patients may have had cancer that was being masked by the very drug prescribed to treat their skin condition. They deserved to know about that risk, and the manufacturers had a responsibility to disclose it.”

The litigation has a direct connection to Tennessee. The first Dupixent wrongful death lawsuit in the country was filed in federal court in Tennessee in October 2025. In that case, a woman developed T-cell lymphoma shortly after beginning Dupixent injections and passed away months later. Her family alleges Sanofi and Regeneron Pharmaceuticals, the drug’s manufacturers, failed to warn patients and doctors about the cancer risk.

Since then, additional lawsuits have been filed in multiple states, and attorneys have filed a motion to consolidate all cases into a federal multidistrict litigation (MDL) in Georgia.

Dupixent was first approved by the FDA in 2017 to treat moderate-to-severe atopic dermatitis. Its approved uses have since expanded to include asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and COPD. The drug generated over $13 billion in revenue in 2024 and is projected to exceed $20 billion in 2026.

The Higgins Firm is reviewing cases for patients who were prescribed Dupixent and were later diagnosed with CTCL, mycosis fungoides, Sézary syndrome, or another form of T-cell lymphoma. Consultations are free and confidential, and clients pay nothing unless the firm recovers compensation on their behalf.

For more information, visit thehigginsfirm.com/dupixent-lawsuit.

About The Higgins Firm

The Higgins Firm is a Nashville-based personal injury law firm with attorneys licensed in Tennessee, Kentucky, Georgia, and Texas. The firm represents clients in catastrophic injury, wrongful death, nursing home abuse, and product liability cases. Since its founding, the firm’s clients have recovered over one hundred million dollars in compensation. For more information, visit thehigginsfirm.com.

200 Hart St

Nashville, TN 37210